Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 127

1.

Distinguishing human peripheral blood CD16+ myeloid cells based on phenotypic characteristics.

Fromm PD, Silveira PA, Hsu JL, Papadimitrious MS, Lo TH, Ju X, Kupresanin F, Romano A, Hsu WH, Bryant CE, Kong B, Abadir E, Mekkawy A, M McGuire H, Groth BFS, Cunningham I, Newman E, Gibson J, Hogarth PM, Hart DNJ, Clark GJ.

J Leukoc Biol. 2019 Nov 21. doi: 10.1002/JLB.5A1119-362RRR. [Epub ahead of print]

PMID:
31749181
2.

CD300f epitopes are specific targets for acute myeloid leukemia with monocytic differentiation.

Abadir E, Gasiorowski RE, Lai K, Kupresanin F, Romano A, Silveira PA, Lo TH, Fromm PD, Kennerson ML, Iland HJ, Ho PJ, Hogarth PM, Bradstock K, Hart DNJ, Clark GJ.

Mol Oncol. 2019 Oct;13(10):2107-2120. doi: 10.1002/1878-0261.12549. Epub 2019 Aug 20.

3.

The role of RASSF proteins in modulating RAS driven lung tumors in vivo.

Harrell Stewart D, Hobbing K, Schmidt ML, Donninger H, Clark GJ.

J Thorac Dis. 2019 May;11(Suppl 9):S1436-S1437. doi: 10.21037/jtd.2019.03.60. No abstract available.

4.

CD83: Activation Marker for Antigen Presenting Cells and Its Therapeutic Potential.

Li Z, Ju X, Silveira PA, Abadir E, Hsu WH, Hart DNJ, Clark GJ.

Front Immunol. 2019 Jun 7;10:1312. doi: 10.3389/fimmu.2019.01312. eCollection 2019. Review.

5.

Examination of CD302 as a potential therapeutic target for acute myeloid leukemia.

Lo TH, Abadir E, Gasiorowski RE, Kabani K, Ramesh M, Orellana D, Fromm PD, Kupresanin F, Newman E, Cunningham I, Hart DNJ, Silveira PA, Clark GJ.

PLoS One. 2019 May 10;14(5):e0216368. doi: 10.1371/journal.pone.0216368. eCollection 2019.

6.

On the Other Side: Manipulating the Immune Checkpoint Landscape of Dendritic Cells to Enhance Cancer Immunotherapy.

Kong BY, Bolton H, Kim JW, Silveira PA, Fromm PD, Clark GJ.

Front Oncol. 2019 Feb 6;9:50. doi: 10.3389/fonc.2019.00050. eCollection 2019. Review.

7.

Targeting the niche: depleting haemopoietic stem cells with targeted therapy.

Abadir E, Bryant C, Larsen S, Clark GJ.

Bone Marrow Transplant. 2019 Jul;54(7):961-968. doi: 10.1038/s41409-019-0445-0. Epub 2019 Jan 21. Review.

PMID:
30664721
8.

RASSF1A Deficiency Enhances RAS-Driven Lung Tumorigenesis.

Schmidt ML, Hobbing KR, Donninger H, Clark GJ.

Cancer Res. 2018 May 15;78(10):2614-2623. doi: 10.1158/0008-5472.CAN-17-2466. Epub 2018 May 7.

9.

Micro-RNA-186-5p inhibition attenuates proliferation, anchorage independent growth and invasion in metastatic prostate cancer cells.

Jones DZ, Schmidt ML, Suman S, Hobbing KR, Barve SS, Gobejishvili L, Brock G, Klinge CM, Rai SN, Park J, Clark GJ, Agarwal R, Kidd LR.

BMC Cancer. 2018 Apr 13;18(1):421. doi: 10.1186/s12885-018-4258-0.

10.

A blood dendritic cell vaccine for acute myeloid leukemia expands anti-tumor T cell responses at remission.

Hsu JL, Bryant CE, Papadimitrious MS, Kong B, Gasiorowski RE, Orellana D, McGuire HM, Groth BFS, Joshua DE, Ho PJ, Larsen S, Iland HJ, Gibson J, Clark GJ, Fromm PD, Hart DN.

Oncoimmunology. 2018 Jan 25;7(4):e1419114. doi: 10.1080/2162402X.2017.1419114. eCollection 2018.

11.

The cell surface phenotype of human dendritic cells.

Clark GJ, Silveira PA, Hogarth PM, Hart DNJ.

Semin Cell Dev Biol. 2019 Feb;86:3-14. doi: 10.1016/j.semcdb.2018.02.013. Epub 2018 Mar 27. Review.

PMID:
29499385
12.

CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma.

Li Z, Ju X, Lee K, Clarke C, Hsu JL, Abadir E, Bryant CE, Pears S, Sunderland N, Heffernan S, Hennessy A, Lo TH, Pietersz GA, Kupresanin F, Fromm PD, Silveira PA, Tsonis C, Cooper WA, Cunningham I, Brown C, Clark GJ, Hart DNJ.

Haematologica. 2018 Apr;103(4):655-665. doi: 10.3324/haematol.2017.178384. Epub 2018 Jan 19.

13.

Investigation of the Role of a Supplementation with Taurine on the Effects of Hypoglycemic-Hypotensive Therapy Against Diabetes-Induced Nephrotoxicity in Rats.

Pandya K, Clark GJ, Lau-Cam CA.

Adv Exp Med Biol. 2017;975 Pt 1:371-400. doi: 10.1007/978-94-024-1079-2_32.

PMID:
28849470
14.

The Effect of Metformin and Taurine, Alone and in Combination, on the Oxidative Stress Caused by Diabetes in the Rat Brain.

Clark GJ, Pandya K, Lau-Cam CA.

Adv Exp Med Biol. 2017;975 Pt 1:353-369. doi: 10.1007/978-94-024-1079-2_31.

PMID:
28849469
15.

The role of the NORE1A tumor suppressor in Oncogene-Induced Senescence.

Barnoud T, Schmidt ML, Donninger H, Clark GJ.

Cancer Lett. 2017 Aug 1;400:30-36. doi: 10.1016/j.canlet.2017.04.030. Epub 2017 Apr 26. Review.

16.

Experimental warming and antecedent fire alter leaf element composition and increase soil C:N ratio in sub-alpine open heathland.

White-Monsant AC, Clark GJ, Ng Kam Chuen MAG, Tang C.

Sci Total Environ. 2017 Oct 1;595:41-50. doi: 10.1016/j.scitotenv.2017.03.237. Epub 2017 Apr 1.

PMID:
28376427
17.

Nonstructural protein 5B promotes degradation of the NORE1A tumor suppressor to facilitate hepatitis C virus replication.

Arora P, Basu A, Schmidt ML, Clark GJ, Donninger H, Nichols DB, Calvisi DF, Kaushik-Basu N.

Hepatology. 2017 May;65(5):1462-1477. doi: 10.1002/hep.29049. Epub 2017 Mar 30.

18.

The Analysis of CD83 Expression on Human Immune Cells Identifies a Unique CD83+-Activated T Cell Population.

Ju X, Silveira PA, Hsu WH, Elgundi Z, Alingcastre R, Verma ND, Fromm PD, Hsu JL, Bryant C, Li Z, Kupresanin F, Lo TH, Clarke C, Lee K, McGuire H, Fazekas de St Groth B, Larsen SR, Gibson J, Bradstock KF, Clark GJ, Hart DN.

J Immunol. 2016 Dec 15;197(12):4613-4625. Epub 2016 Nov 11.

19.

CMRF-56(+) blood dendritic cells loaded with mRNA induce effective antigen-specific cytotoxic T-lymphocyte responses.

Fromm PD, Papadimitrious MS, Hsu JL, Van Kooten Losio N, Verma ND, Lo TH, Silveira PA, Bryant CE, Turtle CJ, Prue RL, Vukovic P, Munster DJ, Nagasaki T, Barnard RT, Mahler SM, Anguille SA, Berneman Z, Horvath LG, Bradstock KF, Joshua DE, Clark GJ, Hart DN.

Oncoimmunology. 2016 May 5;5(6):e1168555. doi: 10.1080/2162402X.2016.1168555. eCollection 2016 Jun.

20.

Characterization of the Expression and Function of the C-Type Lectin Receptor CD302 in Mice and Humans Reveals a Role in Dendritic Cell Migration.

Lo TH, Silveira PA, Fromm PD, Verma ND, Vu PA, Kupresanin F, Adam R, Kato M, Cogger VC, Clark GJ, Hart DN.

J Immunol. 2016 Aug 1;197(3):885-98. doi: 10.4049/jimmunol.1600259. Epub 2016 Jun 17.

21.

Nore1a drives Ras to flick the P53 senescence switch.

Donninger H, Clark GJ.

Mol Cell Oncol. 2015 Jun 10;3(3):e1055050. doi: 10.1080/23723556.2015.1055050. eCollection 2016 May.

22.

Ras signaling through RASSF proteins.

Donninger H, Schmidt ML, Mezzanotte J, Barnoud T, Clark GJ.

Semin Cell Dev Biol. 2016 Oct;58:86-95. doi: 10.1016/j.semcdb.2016.06.007. Epub 2016 Jun 8. Review.

23.

A multi-laboratory comparison of blood dendritic cell populations.

Fromm PD, Kupresanin F, Brooks AE, Dunbar PR, Haniffa M, Hart DN, Clark GJ.

Clin Transl Immunology. 2016 Apr 8;5(4):e68. doi: 10.1038/cti.2016.5. eCollection 2016 Apr.

24.

Rheb may complex with RASSF1A to coordinate Hippo and TOR signaling.

Nelson N, Clark GJ.

Oncotarget. 2016 Jun 7;7(23):33821-31. doi: 10.18632/oncotarget.8447.

25.

NORE1A Regulates MDM2 Via β-TrCP.

Schmidt ML, Calvisi DF, Clark GJ.

Cancers (Basel). 2016 Mar 23;8(4). pii: E39. doi: 10.3390/cancers8040039.

26.

NORE1A is a double barreled Ras senescence effector that activates p53 and Rb.

Donninger H, Barnoud T, Clark GJ.

Cell Cycle. 2016 Sep;15(17):2263-4. doi: 10.1080/15384101.2016.1152431. Epub 2016 Feb 26.

27.

New insights into the phenotype of human dendritic cell populations.

Clark GJ, Kupresanin F, Fromm PD, Ju X, Muusers L, Silveira PA, Elgundi Z, Gasiorowski RE, Papadimitrious MS, Bryant C, Lee KM, Clarke CJ, Young JW, Chan A, Harman A, Botting R, Cabezón R, Benitez-Ribas D, Brooks AE, Dunbar PR, Hart DN.

Clin Transl Immunology. 2016 Jan 29;5(1):e61. doi: 10.1038/cti.2015.40. eCollection 2016 Jan.

28.

Ras Regulates Rb via NORE1A.

Barnoud T, Donninger H, Clark GJ.

J Biol Chem. 2016 Feb 5;291(6):3114-23. doi: 10.1074/jbc.M115.697557. Epub 2015 Dec 16.

29.

Comparison of taurine and pantoyltaurine as antioxidants in vitro and in the central nervous system of diabetic rats.

Patel SN, Pandya K, Clark GJ, Parikh MC, Lau-Cam CA.

Exp Toxicol Pathol. 2016 Feb-Mar;68(2-3):103-12. doi: 10.1016/j.etp.2015.11.002. Epub 2015 Nov 23.

PMID:
26616540
30.

A porcine model system of BRCA1 driven breast cancer.

Donninger H, Hobbing K, Schmidt ML, Walters E, Rund L, Schook L, Clark GJ.

Front Genet. 2015 Aug 25;6:269. doi: 10.3389/fgene.2015.00269. eCollection 2015.

31.

Immunosuppressive human anti-CD83 monoclonal antibody depletion of activated dendritic cells in transplantation.

Seldon TA, Pryor R, Palkova A, Jones ML, Verma ND, Findova M, Braet K, Sheng Y, Fan Y, Zhou EY, Marks JD, Munro T, Mahler SM, Barnard RT, Fromm PD, Silveira PA, Elgundi Z, Ju X, Clark GJ, Bradstock KF, Munster DJ, Hart DN.

Leukemia. 2016 Mar;30(3):692-700. doi: 10.1038/leu.2015.231. Epub 2015 Aug 19.

PMID:
26286117
32.

Succulent species differ substantially in their tolerance and phytoextraction potential when grown in the presence of Cd, Cr, Cu, Mn, Ni, Pb, and Zn.

Zhang C, Sale PW, Clark GJ, Liu W, Doronila AI, Kolev SD, Tang C.

Environ Sci Pollut Res Int. 2015 Dec;22(23):18824-38. doi: 10.1007/s11356-015-5046-x. Epub 2015 Jul 24.

PMID:
26201657
33.

Taurine can enhance the protective actions of metformin against diabetes-induced alterations adversely affecting renal function.

Pandya KG, Budhram R, Clark GJ, Lau-Cam CA.

Adv Exp Med Biol. 2015;803:227-50. doi: 10.1007/978-3-319-15126-7_20. No abstract available.

PMID:
25833502
34.

NORE1A is a Ras senescence effector that controls the apoptotic/senescent balance of p53 via HIPK2.

Donninger H, Calvisi DF, Barnoud T, Clark J, Schmidt ML, Vos MD, Clark GJ.

J Cell Biol. 2015 Mar 16;208(6):777-89. doi: 10.1083/jcb.201408087.

35.

Magnetic nanoparticle-supported lipid bilayers for drug delivery.

Mattingly SJ, O'Toole MG, James KT, Clark GJ, Nantz MH.

Langmuir. 2015 Mar 24;31(11):3326-32. doi: 10.1021/la504830z. Epub 2015 Mar 11.

PMID:
25714501
36.

Human polymorphonuclear neutrophils specifically recognize and kill cancerous cells.

Yan J, Kloecker G, Fleming C, Bousamra M 2nd, Hansen R, Hu X, Ding C, Cai Y, Xiang D, Donninger H, Eaton JW, Clark GJ.

Oncoimmunology. 2014 Jul 3;3(7):e950163. eCollection 2014.

37.

RASSF6 exhibits promoter hypermethylation in metastatic melanoma and inhibits invasion in melanoma cells.

Mezzanotte JJ, Hill V, Schmidt ML, Shinawi T, Tommasi S, Krex D, Schackert G, Pfeifer GP, Latif F, Clark GJ.

Epigenetics. 2014 Nov;9(11):1496-503. doi: 10.4161/15592294.2014.983361.

38.

The RASSF1A tumor suppressor regulates XPA-mediated DNA repair.

Donninger H, Clark J, Rinaldo F, Nelson N, Barnoud T, Schmidt ML, Hobbing KR, Vos MD, Sils B, Clark GJ.

Mol Cell Biol. 2015 Jan;35(1):277-87. doi: 10.1128/MCB.00202-14. Epub 2014 Nov 3.

39.

Cell cycle restriction is more important than apoptosis induction for RASSF1A protein tumor suppression.

Donninger H, Clark JA, Monaghan MK, Schmidt ML, Vos M, Clark GJ.

J Biol Chem. 2014 Nov 7;289(45):31287-95. doi: 10.1074/jbc.M114.609537. Epub 2014 Sep 15.

40.

Ras regulates SCF(β-TrCP) protein activity and specificity via its effector protein NORE1A.

Schmidt ML, Donninger H, Clark GJ.

J Biol Chem. 2014 Nov 7;289(45):31102-10. doi: 10.1074/jbc.M114.594283. Epub 2014 Sep 12.

41.

Australian native plant species Carpobrotus rossii (Haw.) Schwantes shows the potential of cadmium phytoremediation.

Zhang C, Sale PW, Doronila AI, Clark GJ, Livesay C, Tang C.

Environ Sci Pollut Res Int. 2014;21(16):9843-51. doi: 10.1007/s11356-014-2919-3. Epub 2014 Apr 30.

PMID:
24777324
42.

Microtubule segment stabilization by RASSF1A is required for proper microtubule dynamics and Golgi integrity.

Arnette C, Efimova N, Zhu X, Clark GJ, Kaverina I.

Mol Biol Cell. 2014 Mar;25(6):800-10. doi: 10.1091/mbc.E13-07-0374. Epub 2014 Jan 29.

43.

Antibody therapy for acute myeloid leukaemia.

Gasiorowski RE, Clark GJ, Bradstock K, Hart DN.

Br J Haematol. 2014 Feb;164(4):481-95. doi: 10.1111/bjh.12691. Epub 2013 Dec 10. Review.

PMID:
24321020
44.

Strategies for preventing distractions and interruptions in the OR.

Clark GJ.

AORN J. 2013 Jun;97(6):702-7. doi: 10.1016/j.aorn.2013.01.018.

PMID:
23722034
45.

RASSF Family Proteins.

Clark GJ, Baksh S, Latif F, Lim DS.

Mol Biol Int. 2012;2012:938916. doi: 10.1155/2012/938916. Epub 2012 Dec 10. No abstract available.

46.

CD300 molecule regulation of human dendritic cell functions.

Gasiorowski RE, Ju X, Hart DN, Clark GJ.

Immunol Lett. 2013 Jan;149(1-2):93-100. doi: 10.1016/j.imlet.2012.10.005. Epub 2012 Oct 13. Review.

PMID:
23072861
47.

RASSF1A and the Taxol Response in Ovarian Cancer.

Kassler S, Donninger H, Birrer MJ, Clark GJ.

Mol Biol Int. 2012;2012:263267. doi: 10.1155/2012/263267. Epub 2012 Apr 3.

48.

Hydrophobic oxime ethers: a versatile class of pDNA and siRNA transfection lipids.

Biswas S, Knipp RJ, Gordon LE, Nandula SR, Gorr SU, Clark GJ, Nantz MH.

ChemMedChem. 2011 Nov 4;6(11):2063-9. doi: 10.1002/cmdc.201100259. Epub 2011 Aug 31.

49.

Salvador protein is a tumor suppressor effector of RASSF1A with hippo pathway-independent functions.

Donninger H, Allen N, Henson A, Pogue J, Williams A, Gordon L, Kassler S, Dunwell T, Latif F, Clark GJ.

J Biol Chem. 2011 May 27;286(21):18483-91. doi: 10.1074/jbc.M110.214874. Epub 2011 Apr 13.

50.

Click assembly of magnetic nanovectors for gene delivery.

Biswas S, Gordon LE, Clark GJ, Nantz MH.

Biomaterials. 2011 Apr;32(10):2683-8. doi: 10.1016/j.biomaterials.2010.12.047. Epub 2011 Jan 20.

Supplemental Content

Loading ...
Support Center